FDA Reform Bill Would Give Commissioner Fixed Term, Add Review Board
This article was originally published in The Tan Sheet
Executive Summary
The Transforming the Regulatory Environment to Accelerate Access to Treatments Act would mandate a fixed six-year term for the FDA commissioner and the agency’s centers would receive a chief medical policy officer, according to a draft of the bill.
You may also be interested in...
FDA's Office of Medical Policy Grows Into A "Super Office"; DDMAC Gets A Promotion
The Office of Medical Policy now houses the Office of Prescription Drug Promotion (formerly DDMAC) and the newly created Office of Medical Policy Initiatives.